Table Info

Table 1.

Treatments and features

Treatment	Benefits	Negative consequences
Surgery	Removal of a brain metastasis, immediate elimination of life-threatening or symptom-generating mass effects and elimination of the source of perifocal edema, a survival benefit	Surgery risk and problems, surgical technique for detecting distinct tumor size, location
WBRT	Improved survival	Hair loss, fatigue, headache, skin erythema, and serous otitis media
SRS	Improved survival	Nausea, vomiting, fatigue
Chemotherapy	Live longer, reducing cancer symptoms	Fatigue, hair loss, loss of appetite, nausea, skin and nail problems bowel issues such as constipation or diarrhea, mouth sores
Targeting responsible molecular mechanisms	Minimizing the impact of side effects, live longer, reducing cancer symptoms, improves a patient’s response to treatment	Interventions with normal functions
Nano drug	Minimizing the impact of side effects, improves a patient’s response to treatment, passing through the BBB more effectively	Designing

Declarations

Author contributions

ZKD: Conceptualization, Investigation, Writing—original draft, Writing—review & editing. The author read and approved the submitted version.

Conflicts of interest

The author declares that there are no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J Neurooncol. 2005;75:5–14. [DOI] [PubMed]

Achrol AS, Rennert RC, Anders C, Soffietti R, Ahluwalia MS, Nayak L, et al. Brain metastases. Nat Rev Dis Primers. 2019;5:5. [DOI] [PubMed]

Svokos KA, Salhia B, Toms SA. Molecular biology of brain metastasis. Int J Mol Sci. 2014;15:9519–30. [DOI] [PubMed] [PMC]

Fidler IJ. The role of the organ microenvironment in brain metastasis. Semin Cancer Biol. 2011;21:107–12. [DOI] [PubMed]

Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14:48–54. [DOI] [PubMed]

Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res. 2010;16:5664–78. [DOI] [PubMed] [PMC]

Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M, et al. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells. 2011;29:32–45. [DOI] [PubMed]

Junttila MR, Evan GI. p53-a Jack of all trades but master of none. Nat Rev Cancer. 2009;9:821–9. [DOI] [PubMed]

Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001;7:1194–201. [DOI] [PubMed]

10.

Arshad F, Wang L, Sy C, Avraham S, Avraham HK. Blood-brain barrier integrity and breast cancer metastasis to the brain. Patholog Res Int. 2010;2011:920509. [DOI] [PubMed] [PMC]

11.

Hermann PC, Bhaskar S, Cioffi M, Heeschen C. Cancer stem cells in solid tumors. Semin Cancer Biol. 2010;20:77–84. [DOI] [PubMed]

12.

Ali S, Górska Z, Duchnowska R, Jassem J. Molecular profiles of brain metastases: a focus on heterogeneity. Cancers (Basel). 2021;13:2645. [DOI] [PubMed] [PMC]

13.

Nallanthighal S, Heiserman JP, Cheon DJ. The role of the extracellular matrix in cancer stemness. Front Cell Dev Biol. 2019;7:86. [DOI] [PubMed] [PMC]

14.

Ingangi V, Minopoli M, Ragone C, Motti ML, Carriero MV. Role of microenvironment on the fate of disseminating cancer stem cells. Front Oncol. 2019;9:82. [DOI] [PubMed] [PMC]

15.

Książkiewicz M, Markiewicz A, Zaczek AJ. Epithelial-mesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells. Pathobiology. 2012;79:195–208. [DOI] [PubMed]

16.

Chen T, You Y, Jiang H, Wang ZZ. Epithelial-mesenchymal transition (EMT): a biological process in the development, stem cell differentiation, and tumorigenesis. J Cell Physiol. 2017;232:3261–72. [DOI] [PubMed] [PMC]

17.

Jing Y, Han Z, Zhang S, Liu Y, Wei L. Epithelial-mesenchymal transition in tumor microenvironment. Cell Biosci. 2011;1:29. [DOI] [PubMed] [PMC]

18.

Banyard J, Bielenberg DR. The role of EMT and MET in cancer dissemination. Connect Tissue Res. 2015;56:403–13. [DOI] [PubMed] [PMC]

19.

Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–96. [DOI] [PubMed] [PMC]

20.

Margarido AS, Uceda-Castro R, Hahn K, de Bruijn R, Kester L, Hofland I, et al. Epithelial-to-mesenchymal transition drives invasiveness of breast cancer brain metastases. Cancers (Basel). 2022;14:3115. [DOI] [PubMed] [PMC]

21.

Ganguly D, Chandra R, Karalis J, Teke M, Aguilera T, Maddipati R, et al. Cancer-associated fibroblasts: versatile players in the tumor microenvironment. Cancers (Basel). 2020;12:2652. [DOI] [PubMed] [PMC]

22.

Rahmathulla G, Toms SA, Weil RJ. The molecular biology of brain metastasis. J Oncol. 2012;2012:723541. [DOI] [PubMed] [PMC]

23.

Green CE, Liu T, Montel V, Hsiao G, Lester RD, Subramaniam S, et al. Chemoattractant signaling between tumor cells and macrophages regulates cancer cell migration, metastasis and neovascularization. PLoS One. 2009;4:e6713. [DOI] [PubMed] [PMC]

24.

Rascher G, Fischmann A, Kröger S, Duffner F, Grote EH, Wolburg H. Extracellular matrix and the blood-brain barrier in glioblastoma multiforme: spatial segregation of tenascin and agrin. Acta Neuropathol. 2002;104:85–91. [DOI] [PubMed]

25.

Reuten R, Patel TR, McDougall M, Rama N, Nikodemus D, Gibert B, et al. Structural decoding of netrin-4 reveals a regulatory function towards mature basement membranes. Nat Commun. 2016;7:13515. [DOI] [PubMed] [PMC]

26.

Pal I, Rajesh Y, Banik P, Dey G, Dey KK, Bharti R, et al. Prevention of epithelial to mesenchymal transition in colorectal carcinoma by regulation of the E-cadherin-β-catenin-vinculin axis. Cancer Lett. 2019;452:254–63. Erratum in: Cancer Lett. 2021;499:3. [DOI] [PubMed]

27.

Alsaleem M, Toss MS, Joseph C, Aleskandarany M, Kurozumi S, Alshankyty I, et al. The molecular mechanisms underlying reduced E-cadherin expression in invasive ductal carcinoma of the breast: high throughput analysis of large cohorts. Mod Pathol. 2019;32:967–76. [DOI] [PubMed]

28.

Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis—a look outside the nucleus. Science. 2000;287:1606–9. [DOI] [PubMed]

29.

Ji K, Ye L, Mason MD, Jiang WG. The Kiss-1/Kiss-1R complex as a negative regulator of cell motility and cancer metastasis (review). Int J Mol Med. 2013;32:747–54. [DOI] [PubMed]

30.

Noronha C, Ribeiro AS, Taipa R, Castro DS, Reis J, Faria C, et al. Cadherin expression and EMT: a focus on gliomas. Biomedicines. 2021;9:1328. [DOI] [PubMed] [PMC]

31.

Martins CM, Fernandes BF, Antecka E, Di Cesare S, Mansure JJ, Marshall JC, et al. Expression of the metastasis suppressor gene KISS1 in uveal melanoma. Eye (Lond). 2008;22:707–11. [DOI] [PubMed]

32.

Han SY, Lee M, Hong YK, Hwang S, Choi G, Suh YS, et al. Tsp66E, the drosophila KAI1 homologue, and Tsp74F function to regulate ovarian follicle cell and wing development by stabilizing integrin localization. FEBS Lett. 2012;586:4031–7. [DOI] [PubMed]

33.

Gellersen B, Briese J, Oberndörfer M, Redlin K, Samalecos A, Richter DU, et al. Expression of the metastasis suppressor KAI1 in decidual cells at the human maternal-fetal interface: regulation and functional implications. Am J Pathol. 2007;170:126–39. [DOI] [PubMed] [PMC]

34.

Liao L, Ji X, Ge M, Zhan Q, Huang R, Liang X, et al. Characterization of genetic alterations in brain metastases from non-small cell lung cancer. FEBS Open Bio. 2018;8:1544–52. [DOI] [PubMed] [PMC]

35.

Aljohani HM, Aittaleb M, Furgason JM, Amaya P, Deeb A, Chalmers JJ, et al. Genetic mutations associated with lung cancer metastasis to the brain. Mutagenesis. 2018;33:137–45. [DOI] [PubMed] [PMC]

36.

Xu Y, Qin L, Sun T, Wu H, He T, Yang Z, et al. Twist1 promotes breast cancer invasion and metastasis by silencing foxa1 expression. Oncogene. 2017;36:1157–66. [DOI] [PubMed] [PMC]

37.

Géraud C, Koch PS, Damm F, Schledzewski K, Goerdt S. The metastatic cycle: metastatic niches and cancer cell dissemination. J Dtsch Dermatol Ges. 2014;12:1012–9. English, German. [DOI] [PubMed]

38.

Wilhelm I, Molnár J, Fazakas C, Haskó J, Krizbai IA. Role of the blood-brain barrier in the formation of brain metastases. Int J Mol Sci. 2013;14:1383–411. [DOI] [PubMed] [PMC]

39.

Aberuyi N, Rahgozar S, Khosravi Dehaghi Z, Moafi A, Masotti A, Paolini A. The translational expression of ABCA2 and ABCA3 is a strong prognostic biomarker for multidrug resistance in pediatric acute lymphoblastic leukemia. Onco Targets Ther. 2017;10:3373–80. [DOI] [PubMed] [PMC]

40.

Kunzelmann K. Ion channels and cancer. J Membr Biol. 2005;205:159–73. [DOI] [PubMed]

41.

Pardo LA, del Camino D, Sánchez A, Alves F, Brüggemann A, Beckh S, et al. Oncogenic potential of EAG K (+) channels. EMBO J. 1999;18:5540–7. [DOI] [PubMed] [PMC]

42.

Jahidin AH, Stewart TA, Thompson EW, Roberts-Thomson SJ, Monteith GR. Differential effects of two-pore channel protein 1 and 2 silencing in MDA-MB-468 breast cancer cells. Biochem Biophys Res Commun. 2016;477:731–6. [DOI] [PubMed]

43.

Klumpp L, Sezgin EC, Eckert F, Huber SM. Ion channels in brain metastasis. Int J Mol Sci. 2016;17:1513. [DOI] [PubMed] [PMC]

44.

Sontheimer H. Chloride transport in glioma growth and cell invasion. Physiol Pathol Chloride Transp Channels Nerv Syst. 2010;519. [DOI]

45.

Sontheimer H. An unexpected role for ion channels in brain tumor metastasis. Exp Biol Med (Maywood). 2008;233:779–91. [DOI] [PubMed] [PMC]

46.

Ahluwalia MS, Vogelbaum MV, Chao ST, Mehta MM. Brain metastasis and treatment. F1000Prime Rep. 2014;6:114. [DOI] [PubMed] [PMC]

47.

Bachelot T, Romieu G, Campone M, Diéras V, Cropet C, Dalenc F, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14:64–71. [DOI] [PubMed]

48.

Zhang B, Zeng J, Zhang H, Zhu S, Wang H, He J, et al. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation. Front Immunol. 2022;13:974581. [DOI] [PubMed] [PMC]

49.

Rybarczyk-Kasiuchnicz A, Ramlau R, Stencel K. Treatment of brain metastases of non-small cell lung carcinoma. Int J Mol Sci. 2021;22:593. [DOI] [PubMed] [PMC]

50.

Martin-Algarra S, Hinshelwood R, Mesnage S, Cebon J, Ferrucci PF, Aglietta M, et al. Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a named patient program. Melanoma Res. 2019;29:527–32. [DOI] [PubMed]

51.

Sim S, Wong NK. Nanotechnology and its use in imaging and drug delivery (review). Biomed Rep. 2021;14:42. [DOI] [PubMed] [PMC]

52.

Gao Y, Xie J, Chen H, Gu S, Zhao R, Shao J, et al. Nanotechnology-based intelligent drug design for cancer metastasis treatment. Biotechnol Adv. 2014;32:761–77. [DOI] [PubMed]

53.

Ju X, Chen H, Miao T, Ni J, Han L. Prodrug delivery using dual-targeting nanoparticles to treat breast cancer brain metastases. Mol Pharm. 2021;18:2694–702. [DOI] [PubMed]

54.

Rizzuto MA, Dal Magro R, Barbieri L, Pandolfi L, Sguazzini-Viscontini A, Truffi M, et al. H-ferritin nanoparticle-mediated delivery of antibodies across a BBB in vitro model for treatment of brain malignancies. Biomater Sci. 2021;9:2032–42. [DOI] [PubMed]

55.

Kannan S, Cheng VWT. Nanoparticle drug delivery to target breast cancer brain metastasis: current and future trends. Int J Cancer. 2023;153:1118–29. [DOI] [PubMed]

56.

Kumar M, Rajnikanth PS. A mini-review on HER2 positive breast cancer and its metastasis: resistance and treatment strategies. Curr Nanomed. 2020;10:36–47. [DOI]

57.

Capatina AL, Lagos D, Brackenbury WJ. Targeting ion channels for cancer treatment: current progress and future challenges. Rev Physiol Biochem Pharmacol. 2022;183:1–43. [DOI] [PubMed]

58.

Leanza L, Managò A, Zoratti M, Gulbins E, Szabo I. Pharmacological targeting of ion channels for cancer therapy: in vivo evidences. Biochim Biophys Acta. 2016;1863:1385–97. [DOI] [PubMed]

59.

Grasset EM, Bertero T, Bozec A, Friard J, Bourget I, Pisano S, et al. Matrix stiffening and EGFR cooperate to promote the collective invasion of cancer cells. Cancer Res. 2018;78:5229–42. [DOI] [PubMed]

60.

Huang X, He Y, Dubuc AM, Hashizume R, Zhang W, Reimand J, et al. EAG2 potassium channel with evolutionarily conserved function as a brain tumor target. Nat Neurosci. 2015;18:1236–46. [DOI] [PubMed] [PMC]

61.

Varricchio A, Ramesh SA, Yool AJ. Novel ion channel targets and drug delivery tools for controlling glioblastoma cell invasiveness. Int J Mol Sci. 2021;22:11909. [DOI] [PubMed] [PMC]